eHealth Ventures

FIZE Medical Inc. is a medical device manufacturer based in Modi'in-Maccabim-Re'ut, Israel, established in 2014. The company specializes in developing a device that automates the measurement of urine output, crucial for managing patients' health in intensive care units. This technology facilitates real-time monitoring of urine production, allowing healthcare providers to detect early indicators of kidney function and overall patient status. By integrating into healthcare IT platforms, FIZE Medical's device enhances fluid management and supports timely therapeutic adjustments, ultimately improving patient outcomes and reducing the risk of complications.

DreaMed Diabetes, Ltd. is an Israel-based company founded in 2014 that specializes in developing innovative solutions for diabetes treatment and management. The company has created a portfolio that includes Glucositter, a closed-loop insulin delivery system designed to monitor glucose levels in real-time and optimize insulin adjustments. DreaMed Diabetes is recognized for commercializing the first artificial pancreas technology, which has been validated in leading medical journals. It has also pioneered decision support tools for diabetes management, being the first company to receive FDA clearance for a system utilizing data from continuous glucose monitors and insulin pumps. Its Advisor Pro software, developed by diabetes professionals, leverages artificial intelligence to enable healthcare providers to quickly analyze patient data and recommend personalized treatment plans. Through frequent insulin titration and online monitoring, DreaMed Diabetes aims to enhance patient care by reducing A1C levels and the risk of complications, ensuring that all patients receive high-quality treatment regardless of their location or caregiver.

AccuLine is a digital healthcare company dedicated to preventing heart attacks and saving lives through early detection of coronary artery disease (CAD). The company has developed CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. This innovative platform delivers swift and cost-effective assessments, allowing healthcare providers to identify CAD more effectively and efficiently. By replacing outdated and labor-intensive methods, AccuLine aims to enhance patient outcomes and revolutionize the way heart disease is diagnosed and managed.

Nitur is developing COPatch, a flexible patch equipped with ultrasound micro-transducers that can be easily and quickly placed on a patient’s chest. It provides continuous and accurate hemodynamic data. The ultrasound signals are processed by an AI machine in order to provide an accurate continuous cardiac output parameters.​

Insight Axis uses EEG Analytics proposes to create an algorithm-based platform for predicting the compliance and responsiveness of neuropsychiatric patients to different medications. The platform will enable physicians to predict the patient’s neurobiological response to specific medications before treatment has even begun. The platform will create patient-specific brainwave signatures using data from EEG results. Using this Brain Signature, the algorithm will be able to calculate neuro-markers in the brain and then categorically assess the potential of drug suitability for the individual patient.

Acute Otitis Media (AOM) causes poor conductance of the Chorda Tympani nerve, resulting in its functional impairment, interpreted by the brain as impaired taste sensation. During the inflammation period of AOM, there is a difference in the taste sensation at the two sides of the tongue. While the unaffected side transmits normal taste sensation, on the affected side there is decrease in taste transmission and sensation. The taste buds can be activated with electrical stimulation and the gustatory evoked potentials (GEPs) can be recorded at the cortical gustatory cortex using EEG. Given the observation that AOM is usually unilateral and that the taste sensation on the side of the infection is damaged, electrical stimulation of both sides of the tongue should resulted in different GEPs reading from the infected side compared to the intact side, detecting the presence of AOM. Talma Medical develops a breakthrough innovative technology for accurate clinical diagnostic at home. An over the counter, easy to use and mostly accurate device will make a revolution in the way AOM is diagnosed.

TuneMe is a virtual assistance software that combines artificial intelligence and voice analysis to craft customized treatments incorporating innovative vibroacoustic neuro-stimulation. Using unique technology to rebalance the autonomic nervous system, TuneMe offers a multi-platform neurostimulation solution, specifically designed for individuals experiencing PTSD and sleep difficulties. ​

Wizermed is a health technology company that specializes in migraine relief. It offers a mobile application that leverages data from users' smartwatches to monitor and analyze factors such as sleep patterns and stress levels, which are known triggers for migraines. The app then uses AI to forecast potential migraine attacks, empowering users to take preventive steps and better manage their condition.

ToDX product is an at home diagnostic platform that will perform tests with comparable accuracy to PCR results. The first clinical application of this at-home diagnostic platform will be applied to STI’s (sexually transmitted infections), including chlamydia, gonorrhea, and trichomoniasis. ToDX plans to widen the clinical applications to the respiratory infections, including diagnosis of papillomavirus strains and the diagnosis of upper respiratory virus strains.

Startest is developing an easy-to-use test to detect blood glucose levels in prediabetic patients. The test is designed to be for one-time use and is compatible with an online platform. The test has the same precision as a regular glucose meter, but is administered through Smartest’s patent needle mechanism, which is less painful to patients than traditional blood glucose testing.

IdentifAI Genetics revolutionizes the way prenatal testing is done.

Olive Diagnostics is a company that has developed an innovative passive urine analysis sensor designed to enhance early disease detection and chronic disease management. This sensor, which can be easily mounted to any toilet, utilizes spectroscopy combined with artificial intelligence-based analytics to monitor the urine stream. By continuously collecting and analyzing health data, the device provides users with real-time health alerts that promote awareness of their bodily functions. The technology not only supports individual health management but also offers valuable insights for pharmaceutical and contract research organizations to track drug compliance and usage. With its focus on proactive health monitoring, Olive Diagnostics aims to make urine lab services accessible even in nonindustrial nations, thereby transforming personal health care through advanced, continuous biomarker tracking.

Agamon Health is a healthcare technology company that specializes in improving the management of radiology findings and follow-up recommendations. Its core product, the Agamon Coordinate platform, leverages proprietary deep learning natural language processing technology to automatically extract and structure data from radiology reports. This capability allows healthcare providers to automate workflows, personalize communications, and effectively track adherence to follow-up recommendations. Agamon's platform also aims to break down data silos, facilitating access to both structured and unstructured data that is essential for enhancing medical procedures, diagnostics, and treatment outcomes. By focusing on programs such as lung cancer screenings and the management of incidental findings like pulmonary nodules and aortic aneurysms, Agamon Health enables healthcare professionals to manage complex data at scale, ultimately advancing precision medicine.

Yonalink operates a global network comprising over 30,000 medical centers. It specializes in real-time collection of clinical trial data through its platform, which streamlines electronic health records (EHR) to electronic data capture (EDC), employs AI-driven case report form (CRF) data mapping, and facilitates secure, automated migration of research data from health records. This service enhances trial efficiency, improves data quality, reduces staff burnout at medical centers, and expands access to novel patient care opportunities. Additionally, the platform enables management of clinical trial operations and vendors, accelerates drug and device development, promotes patient diversity and enrollment, and ensures secure, fast, and error-free data capture processes for healthcare providers and researchers.

GaitBetter is a health and wellness company founded in 2017 and headquartered in Hefa, Israel. It focuses on reducing fall risk and improving mobility among the senior adult population through its innovative virtual reality walking platform. This platform uses motor-cognitive training to provide effective rehabilitation and fall prevention solutions. By integrating artificial intelligence and gamification, GaitBetter accelerates patient outcomes and offers personalized interventions that enhance cognitive functions related to safe walking. The company aims to empower seniors to maintain their independence and improve their overall quality of life through advanced technology and tailored therapy.

AccuLine is a digital healthcare company dedicated to preventing heart attacks and saving lives through early detection of coronary artery disease (CAD). The company has developed CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. This innovative platform delivers swift and cost-effective assessments, allowing healthcare providers to identify CAD more effectively and efficiently. By replacing outdated and labor-intensive methods, AccuLine aims to enhance patient outcomes and revolutionize the way heart disease is diagnosed and managed.

Olive Diagnostics is a company that has developed an innovative passive urine analysis sensor designed to enhance early disease detection and chronic disease management. This sensor, which can be easily mounted to any toilet, utilizes spectroscopy combined with artificial intelligence-based analytics to monitor the urine stream. By continuously collecting and analyzing health data, the device provides users with real-time health alerts that promote awareness of their bodily functions. The technology not only supports individual health management but also offers valuable insights for pharmaceutical and contract research organizations to track drug compliance and usage. With its focus on proactive health monitoring, Olive Diagnostics aims to make urine lab services accessible even in nonindustrial nations, thereby transforming personal health care through advanced, continuous biomarker tracking.

RespirAI Medical is a developer of a wearable home monitoring and disease management platform focused on chronic respiratory diseases. The company offers a passive sensor-based device that collects patient data, which is automatically uploaded to the cloud for analysis. Utilizing advanced algorithms powered by artificial intelligence, RespirAI Medical's technology detects deviations from established clinical baselines. This capability allows for the early identification of exacerbations in chronic respiratory conditions, enabling healthcare providers to intervene promptly and enhance patient outcomes. The company's mission is to improve the quality of life for individuals with chronic respiratory issues through reliable and innovative monitoring solutions.

AccuLine is a digital healthcare company dedicated to preventing heart attacks and saving lives through early detection of coronary artery disease (CAD). The company has developed CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. This innovative platform delivers swift and cost-effective assessments, allowing healthcare providers to identify CAD more effectively and efficiently. By replacing outdated and labor-intensive methods, AccuLine aims to enhance patient outcomes and revolutionize the way heart disease is diagnosed and managed.

Symetrify is a company that specializes in digital health solutions aimed at enhancing musculoskeletal function. It develops non-invasive remedies designed to address functional flaws in the neuromusculoskeletal system. Symetrify's innovative technology focuses on treating underlying causes of issues, improving structural motion within the human skeleton, and ultimately preventing pain and disability. The company offers a neuro-mechanical wearable training device that assesses, treats, and prevents spinal kinetic dysfunctions, particularly those associated with chronic low back pain. This device enables patients to receive treatment without the need for painful therapies, promoting long-term improvements in health, performance, and spinal longevity while reducing the risk of injury.

Tiktalk To Me owns and operates a digital health company intended to offer a platform for speech therapy. Its platform functions as a virtual speech therapist, guiding patients through proven and widely accepted training protocols using online games supervised by the patient's personal speech therapist and combines gaming with speech- and voice-recognition technology, enabling speech-language pathologists to shorten the treatment cycle and save substantial time and money for the patients.

HappyDural is a company focused on enhancing anesthetic care through its innovative AI-based system for personalized sedative drug administration management. This system addresses the critical issue of inaccurate dosing by significantly reducing the risks associated with both over-dosing and under-dosing during the entire injection period. Utilizing a sophisticated sensor array and an advanced learning algorithm, HappyDural's solution automates monitoring, allowing for real-time adjustments in anesthesia delivery. This approach not only minimizes life-threatening side effects and pain but also streamlines the administration process, making it compatible with existing medical equipment. Established within the eHealth Ventures incubator, HappyDural aims to provide healthcare providers with a cost-effective and efficient tool for delivering safer, personalized anesthesia care.

Ophthalmic Sciences is focused on innovative solutions for eye health, specifically targeting the management of glaucoma. The company has developed the IOPerfect visor, a groundbreaking device that measures intraocular pressure using a novel non-contact methodology. Resembling goggles, this device automates the process of pressure measurement, providing accurate readings for both eyes without the discomfort associated with traditional methods. By offering a user-friendly and affordable solution, Ophthalmic Sciences aims to address the needs of the 150 million patients globally at risk of blindness due to glaucoma, tapping into a significant market. The team, composed of veterans with over seventy years of combined experience in the field, has garnered $1.4 million in funding to achieve proof of concept and is actively seeking additional financing to prepare for market launch in 2023.

Skelable is a robotics company that develops a medical device that provides rehabilitation for the patient. It helps therapists to treat their patients remotely. The company was founded in 2018 and headquartered in Tel Aviv, Israel

BrainWatch Tech is developing a real-time, continuous, automatic pupil reflex monitoring system for assessing the neurological status of unconscious patients in cases of traumatic brain injury, stroke, and brain surgery. The technology behind BrainWatch is an automatic monitoring system of the pupillary light reflex through closed eyes, using an optical system for image acquisition and AI for image and data analysis. BrainWatch's solution continuously monitors pupillary activity in unconscious patients through closed eyes, immediately alerting surgeons and staff to changes in the patient's condition. The system also enables pupil monitoring in real time during complex brain surgery. The product will look like a pair of virtual reality goggles, equipped with a camera lens and a light that will continuously monitor, measure, and record pupil size and reflex through the closed eyelids of patients with severe brain injury. The continuous monitoring will create a record of the patient's condition and response to treatment over time. BrainWatch Tech was established in the eHealth Ventures incubator, which fosters early-stage digital health start-ups.

Nervio is a digital health company that has created an innovative neuromonitoring solution designed to prevent avoidable paralysis and severe neurological complications during surgical procedures. Utilizing advanced machine learning technologies and clinical intelligence, its real-time system provides automated response assessments, allowing clinicians to receive immediate alerts about potential neurological issues in the operating room. This capability not only reduces the risk of permanent nerve injuries but also enhances operational flexibility, positioning Nervio as a leader in a field that is increasingly open to technological advancements in patient safety and surgical efficacy.

Olive Diagnostics is a company that has developed an innovative passive urine analysis sensor designed to enhance early disease detection and chronic disease management. This sensor, which can be easily mounted to any toilet, utilizes spectroscopy combined with artificial intelligence-based analytics to monitor the urine stream. By continuously collecting and analyzing health data, the device provides users with real-time health alerts that promote awareness of their bodily functions. The technology not only supports individual health management but also offers valuable insights for pharmaceutical and contract research organizations to track drug compliance and usage. With its focus on proactive health monitoring, Olive Diagnostics aims to make urine lab services accessible even in nonindustrial nations, thereby transforming personal health care through advanced, continuous biomarker tracking.

Allerguard Ltd. is a technology company based in Tel Aviv, Israel, that specializes in personal allergy detection systems. Founded in 2017, it has developed a unique hand-held device that enables individuals with food allergies to scan their meals for allergens. Unlike traditional detection devices that require food sampling, Allerguard's system analyzes the vapors emitted by food, allowing it to detect allergen particles with precision. The device alerts users to the presence of allergens, ensuring they can make informed decisions about food consumption in real-time. This innovative approach is designed to enhance safety for those with allergies, focusing on the chemical and physical properties of specific allergens such as peanuts and tree nuts.

Ophthalmic Sciences is focused on innovative solutions for eye health, specifically targeting the management of glaucoma. The company has developed the IOPerfect visor, a groundbreaking device that measures intraocular pressure using a novel non-contact methodology. Resembling goggles, this device automates the process of pressure measurement, providing accurate readings for both eyes without the discomfort associated with traditional methods. By offering a user-friendly and affordable solution, Ophthalmic Sciences aims to address the needs of the 150 million patients globally at risk of blindness due to glaucoma, tapping into a significant market. The team, composed of veterans with over seventy years of combined experience in the field, has garnered $1.4 million in funding to achieve proof of concept and is actively seeking additional financing to prepare for market launch in 2023.

EFA is a developer of innovative diagnostic tools focused on making testing and diagnostics both affordable and accessible. The company's flagship product, RevDx (Revolutionary Diagnostics), is a portable, handheld device that performs automated blood tests and infectious disease diagnostics with a simple finger prick. This technology eliminates the need for laboratory conditions, enabling healthcare professionals to make real-time decisions regarding treatments, such as the necessity of antibiotic use. By providing on-the-spot diagnostics and integrating data analytics, EFA empowers physicians and medical researchers to deliver accurate diagnoses and enhance patient care globally.

TrainPain is an innovative digital therapeutics company based in Tel Aviv-Yafo, Israel, focused on developing a novel treatment for chronic neuropathic pain. The company leverages technological advancements to address pain-related hypersensitivity in the nervous system through a platform that combines wearable hardware with personalized sensory training games. This interactive approach includes both virtual reality and mobile applications, allowing patients to engage in rehabilitation either in clinical settings or at home. TrainPain's platform is designed to assess and treat neuroplasticity related to chronic pain using a proprietary tactile stimulation device and sensory perception tasks integrated into engaging video games. By offering a unique blend of distraction and rehabilitation, TrainPain aims to improve the mental and emotional well-being of individuals suffering from conditions such as neuropathic pain and fibromyalgia.

SensoGenic Inc., established in 2016 and headquartered in Ness Ziona, Israel, specializes in developing diagnostic biosensors for food allergen detection. The company offers portable, handheld devices and digital analyzers designed for consumers, enabling them to test food items for allergens on-the-go. SensoGenic's innovative technology uses biosensors to detect allergens without physical contact, providing users with real-time results via a mobile application. This allows individuals with food allergies to safely consume meals at restaurants or social gatherings by avoiding allergic reactions.

Allerguard Ltd. is a technology company based in Tel Aviv, Israel, that specializes in personal allergy detection systems. Founded in 2017, it has developed a unique hand-held device that enables individuals with food allergies to scan their meals for allergens. Unlike traditional detection devices that require food sampling, Allerguard's system analyzes the vapors emitted by food, allowing it to detect allergen particles with precision. The device alerts users to the presence of allergens, ensuring they can make informed decisions about food consumption in real-time. This innovative approach is designed to enhance safety for those with allergies, focusing on the chemical and physical properties of specific allergens such as peanuts and tree nuts.

DermaDetect is a developer of an AI-driven digital dermatology platform that focuses on the analysis and management of skin disorders, including non-pigmented lesions and acute diseases. The platform allows patients to conduct self-assessments of their skin, hair, and nails, facilitating remote diagnosis and treatment of various skin conditions. By automatically detecting skin issues, DermaDetect not only recommends appropriate treatments but also connects patients with nearby physicians, ensuring they receive timely care from the comfort of their homes. This innovative approach empowers individuals to manage their dermatological health effectively and conveniently.

Tiktalk To Me owns and operates a digital health company intended to offer a platform for speech therapy. Its platform functions as a virtual speech therapist, guiding patients through proven and widely accepted training protocols using online games supervised by the patient's personal speech therapist and combines gaming with speech- and voice-recognition technology, enabling speech-language pathologists to shorten the treatment cycle and save substantial time and money for the patients.